Daria V. Babushok, MD, PhD, offers a retrospective on myeloproliferative disease with an overview of the 2016 revision of the WHO criteria for Philadelphia-chromosome negative (PCN) myeloproliferative neoplasms (MPNs) and familial MPN before discussing risk-stratification for MPN; and therapies for the classical PCN subtypes essential thrombocytosis, polycythemia vera and primary myelofibrosis (including allogeneic stem cell transplantation and non-transplant therapies  for the latter). Dr. Babushok’s examination of the myeloproliferative diseases concludes with an overview of chronic myelogenous leukemia, a Philadelphia chromosome positive disease state.